CHRS Stock Analysis: Buy, Sell, or Hold?
CHRS - Coherus Oncology, Inc. Common Stock
$1.36
-0.06 (-4.23%)
âŧ
5d:
+18.26%
30d:
-3.55%
90d:
-15.53%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When CHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CHRS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CHRS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CHRS is currently trading at $1.36, which is considered fair relative to its 30-day fair value range of $1.25 to $1.46.
Technical Outlook: Technically, CHRS is in a strong downtrend. Immediate support is located at $1.13, while resistance sits at $1.44. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.75 (+469.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CHRS is in a strong downtrend. Immediate support is located at $1.13, while resistance sits at $1.44. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.75 (+469.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.25 -
$1.46
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 469.9% below Wall St target ($7.75)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.25 -
$1.46
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.13
Resistance Level
$1.44
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.16
Wall Street Target
$7.75
(+469.9%)
Revenue Growth (YoY)
39.5%
Earnings Growth (YoY)
-75.5%
Profit Margin
-259.4%
Share & Embed Analysis
Last updated: August 24, 2026 6:42 PM ET
Data refreshes hourly during market hours. Next update: 7:42 PM
Data refreshes hourly during market hours. Next update: 7:42 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 48 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 37 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 40 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 62 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 33 SELL |
